Background: To our knowledge, no reports have evaluated the effects of genetic polymorphisms of insulin-like growth factor-I (IGF-I) on clinical outcomes of gastric cancer patients. 
introduction
Gastric cancer is the fourth most common malignancy in the world (989 000 cases in 2008, 7.8% of total) and the second leading cause of cancer deaths (737 000 deaths, 9.7% of total) [1] . The most effective treatment of localized disease is surgery, but approximately half of patients with advanced-stage disease develop recurrence after curative resection [2, 3] . Although adjuvant chemotherapy and perioperative chemoradiotherapy are reported to decrease the recurrence rate of gastric cancer, the efficacy is not satisfactory [2] [3] [4] [5] . The prognosis of patients with unresectable or recurrent gastric cancer remains poor, as chemotherapy confers only a minimal survival advantage, with a median survival of 1 year [5, 6] . Therefore, identifying patients at high risk for recurrence and developing more effective adjuvant treatments are necessary for improving survival in gastric cancer.
The signaling pathway involving insulin-like growth factor-I (IGF-I) plays an important role in cell growth and differentiation [7, 8] . Additionally, IGF-I affects tumor cell proliferation via the RAS-RAF-MAP kinase signaling pathway and also has antiapoptotic effects mediated by the phosphatidylinositol-3 kinase/AKT pathway, which ultimately activates downstream transcription factors that regulate the gene expression of proliferative, differentiation, and antiapoptotic factors [7, 8] . Considering the important roles of the IGF-I pathway in stimulating cellular growth, influencing apoptosis, and inhibiting invasion and metastasis, it is conceivable that genetic polymorphisms in IGF-I genes may affect the progression and recurrence of cancer. Although a few reports have evaluated the impact of genetic polymorphisms of IGF-I and other molecules of the IGF-I axis on the clinical outcomes of various tumor types [9] [10] [11] , to our knowledge, the effect of IGF-I genetic polymorphism in gastric cancer has not been examined.
To address this issue, we carried out a retrospective cohort study to analyze the impact of IGF-I genetic polymorphisms on recurrence-free survival (RFS) using data from the Hospitalbased Epidemiologic Research Program at Aichi Cancer Center (HERPACC) combined with clinical data from Aichi Cancer Center Hospital (ACCH), Japan.
materials and methods patients
Patients were selected from the database of the HERPACC, which was conducted at ACCH. Details of the HERPACC have been described elsewhere [12, 13] . In brief, 23 408 HERPACC-enrolled first-visit outpatients treated between January 2001 and November 2005 were asked to provide blood samples in addition to information on lifestyle factors. Of those who participated, 22 727 (97.1%) subjects satisfactorily completed a self-administered questionnaire. The study was approved by the Institutional Ethical Committee of ACCH.
In the present study, patients with newly diagnosed gastric cancer who participated in HERPACC and met the following criteria were included: (i) presence of histologically or cytologically proven operable gastric cancer, (ii) underwent curative gastrectomy with adequate lymph node dissection, and (iii) blood samples were available for the analysis of genetic polymorphisms.
During the HERPACC, 1120 patients with gastric cancer were referred to our hospital. Of these, 933 patients completed the HERPACC questionnaire and 708 patients underwent blood sampling. Among them, 430 patients met the enrollment criteria and were included as subjects in this study.
selection and evaluation of genetic polymorphisms
In this study, we took a tag single nucleotide polymorphism (SNP) approach to examine association between chromosomal regions where IGF-I locates. Tag SNPs are marker loci that are selected based on linkage disequilibrium (LD) in the region rather than on function of the loci. It enables to avoid redundancy of multiple loci information in the analysis. As a nature of this selection process, not all loci examined in this analysis have functional information. The SNP loci of the IGF-I gene examined in this study were selected using the tag SNP picker program, which is available on the International HapMap Project website (http://hapmap.ncbi.nlm.nih.gov) and is based on the HapMap database for Japanese in Tokyo (build 36) [14, 15] . The selection criteria for each locus were (i) minor allele frequency (MAF) >30% and (ii) haplotype R 2 value >0.80. Finally, we selected 10 loci (rs5742714, rs6214, rs1520220, rs6539035, rs4764887, rs2288378, rs2195239, rs12423791, rs2162679, and rs5742612) to cover the IGF-I gene. DNA was extracted from the buffy coat fraction of whole blood collected from each subject using a Blood Mini Kit (Qiagen K.K., Tokyo, Japan). Extracted DNA was analyzed using the polymerase chain reaction (PCR) TaqMan method [16] with the EP1 SNP Genotyping 96.96 Dynamic Array (Fluidigm, San Francisco, CA). We validated the genotyping results for 5% of the samples by checking consistency in duplicated examination using the 7500 Fast Real-time PCR System (Applied Biosystems, Foster City, CA), and found 100% consistency.
evaluation of treatment and statistical methods
The primary purpose of this study was to evaluate the association between IGF-I genetic polymorphisms and RFS, which was defined as the interval between the date of gastrectomy and the date of recurrence or death. Overall survival (OS) from the date of gastrectomy to the date of death or last follow-up was also measured. We applied RFS as the primary end point to evaluate the prognosis of gastric cancer rather than OS, since chemotherapy after recurrence may have confounded the OS results.
Tumor recurrence was determined by means of imaging studies, including computed tomography (CT), ultrasonography, gastrointestinal radiography series, and endoscopy. Patients typically underwent at least one type of imaging study, predominantly CT, at 6-month intervals during the first 2 years after surgery, and at 1-year intervals thereafter, until 5 years after the initial surgery.
Patients' vital or disease status was confirmed by examining the medical records of the last follow-up visit. For patients lost to followup, vital status was confirmed by the annually conducted census registration.
To evaluate the effect of genetic polymorphisms of IGF-I on RFS and OS, both univariate and multivariate Cox proportional hazard models were applied. Therefore, the measure of association in this study was the hazard ratio (HR) together with the 95% confidence interval (95% CI). We examined four models for each locus such as, (i) per-allele model (log additive), (ii) genotype model relative to the major homozygote, (iii) dominant model, and (iv) recessive model, to identify potentially significant loci for further evaluation and select the most appropriate model. We set the threshold P-value for further evaluation as a value <0.05. Confounding variables considered in the multivariate analyses were age (<65 versus ‡65 years), gender (male: 0 versus female: 1), history of diabetes (no: 0 versus yes: 1), pathological stage according to the Japanese classification [17] (stage 1-4), histological subtype (diffuse: 0 versus intestinal: 1), and adjuvant chemotherapy (no: 0 versus yes: 1). We explored the interaction between selected loci and confounders by including an interaction term in the per-allele model. The Kaplan-Meier product-limit method was applied to estimate survival probability at specific time points.
We evaluated LD by means of LD coefficients (D'). LD status in the study subjects was depicted using Haploview version 4.2 software (Broad Institute, Cambridge, MA) [18] .
Distribution of subject characteristics was assessed by the chi-square test or Fisher's exact test, as appropriate. Statistical analyses were carried out using STATA version 10 (StataCorp LP, College Station, TX). All tests were two-sided, and P-values <0.05 were considered statistically significant. Table 1 . Most patients in this study had early pathological stage gastric cancer (80.0% stage I-II versus 20.0% stage III-IV). Since nearly all patients underwent gastrectomy before the results of the ACTS-GC study, which established adjuvant chemotherapy with the oral fluoropyrimidine S-1 in stage II and III gastric cancer in Japan [4] , few patients (6%) received adjuvant chemotherapy in this study cohort. In addition, no patients received neoadjuvant chemotherapy or perioperative chemoradiotherapy. The frequencies and types of the 10 identified SNP IGF-I polymorphisms are shown in Figure 1 and Table 2 . Genotype distributions of the 10 polymorphisms, with the exception of rs6539035, were in accordance with Hardy-Weinberg equilibrium and the MAF of these polymorphisms were almost similar to those of Japanese in Tokyo in HapMap (Table 3 ). In the subsequent analyses, we therefore excluded the rs6539035 polymorphism. influence of IGF-I genetic polymorphism on RFS Table 2 summarizes the univariate and multivariate analyses of genetic polymorphisms of IGF-I as prognostic factors for improved RFS. In the per-allele model multivariate analysis, the SNPs rs1520220 and rs2195239 were significantly associated with RFS (P < 0.02 and P < 0.01, respectively). According to the genotype analysis, the minor homotype (G/G type) of rs1520220 was significantly associated with improved RFS (HR 0.33; 95% CI 0.13-0.83; P-value = 0.02) compared with the major homotype (C/C type). In addition, the minor homotype (C/C type) of rs2195239 was also associated with improved RFS compared with the major homotype (G/G type) (HR 0.30; 95% CI 0.12-0.77; P-value = 0.01). The other evaluated polymorphisms had no impact on RFS. Multivariate analyses of the association of genetic polymorphisms with OS showed similar results, with the identical two polymorphisms found to have a significant impact (Supplemental Table S1 , available at Annals of Oncology online). We did not conduct the haplotype analysis, since the LD between rs1520220 and rs2195239 was high (R 2 = 0.75; D' = 0.96). interaction of genetic polymorphisms and pathological stage
Since the LD between rs1520220 and rs2195239 was high, the interactions between several background characteristics and only rs1520220 are shown in Table 4 . When we stratified patients according to stage (I-II versus III-IV), the impact of rs1520220 was particularly prominent in patients with advanced-stage cancer, with a P-value for interaction of 0.01 (Table 4 ). The 5-year RFS rate of patients with stage I-II according to the rs1520220 genotype was 93.4% for CC (95% CI 86.0-97.0), 92.6% for CG (95% CI 87.0-95.9), and 94.8% for GG (95% CI 86.7-98.0), while that for patients with stage III-IV was 31.6% for CC (95% CI 12.9-52.3), 54.2% for CG (95% CI 38.6-67.5), and 77.8% for GG (95% CI 51.1-91.0) (Figure 2) . No other significant interactions were observed.
discussion
In this study, we systematically evaluated 10 tag SNPs of the IGF-I gene and identified two SNPs (rs1520220 and rs2195239) that demonstrated significant association with RFS in gastric cancer patients who had undergone curative gastrectomy. Notably, the association was more prominent in advanced stages of disease, with significant interaction. To our knowledge, this study represents the first report of a relationship between IGF-I polymorphisms and RFS in patients with gastric cancer. These data suggest that IGF axis gene polymorphisms may be associated with gastric cancer progression, and that these associations may be modified by stage.
Our results indicate carriers of the minor G allele (rs1520220) in the IGF-I gene have a significant decrease in the risk of recurrence for gastric cancer. As the SNP is located at an intron boundary, this variant allele may lead to alternative splicing of IGF-I mRNA and altered protein function, although no direct evidence is available at present to support this speculation. Moreover, as it has been reported that the G allele of rs1520220 is associated with decreased circulating IGF-I [19, 20] , the observed association between this allele and RFS might be due to a low rate of tumor recurrence resulting from low IGF-I expression. However, it is also possible that another locus in LD with the rs1520220 polymorphism is responsible for the improved RFS. Despite these speculations, the exact effect of this polymorphism on IGF-I is unclear, and further research is needed to characterize this polymorphism in greater detail.
The other identified polymorphism that was significantly associated with RFS was rs2195239, which is located in the promoter region near the transcription start site of IGF-I. Although the impact of this polymorphism on IGF-I function is also unknown, we determined that carriers of the minor C allele are associated with a low rate of recurrence compared with those with the wild-type allele. A few studies have evaluated the effect of rs2195239 on circulating IGF-I levels; however, unlike rs1520220, a significant correlation was not found [21, 22] . It is possible that the association of the SNP alleles of rs2195239 with survival may be mediated through their LD with rs1520220, or vice versa. However, our present results should be validated in a study that examines circulating IGF-I and the pathological evaluation of IGF-I expression in tumor tissue.
Our study findings, which demonstrated a relationship between IGF-I polymorphisms and RFS, provide supporting evidence for the importance of genes from the IGF axis in the recurrence of gastric cancer. The genetic markers identified in this study, rs1520220 and rs2195239 that were determined from blood samples collected noninvasively, might have important clinical implications. For example, these genotypes might be useful in selecting patients for IGF-I-targeted therapy that has been recently evaluated in several types of cancers [23] . Gastric cancer patients carrying the variant alleles with high risk for recurrence might be suitable candidates for such targeted therapy.
The methodological strengths and limitations of our study warrant mention. The strengths include the relatively large sample size and detailed clinical information of patients, such as pathological type and disease stage. In addition, since a low proportion of our patients received adjuvant chemotherapy, our results reflect tumor characteristics alone, without the possible influence of perioperative therapy. Lastly, given that the observed allele frequencies were comparable to those previously reported in public databases, bias in the distribution of selected polymorphisms was negligible. The limitations of this study include the limited number of polymorphisms examined and the potential false-positive findings related to multiple comparisons.
In conclusion, this represents the first report to evaluate the effects of IGF-I genetic polymorphisms on clinical outcomes of patients with gastric cancer. Our findings indicate that IGF-I polymorphisms may play an important role in recurrence after curative resection. Further prospective evaluation is warranted.
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